Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice

Neuroscience

Volumn 140, Issue 2, 2006, Pages 607-622

  Zhu, J P Q ^a   Xu, W ^a   Angulo, J A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

apoptosis; interneurons; methamphetamine; projection neurons; striatum

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE ACETYLTRANSFERASE; CYCLIC AMP; DOPAMINE; METHAMPHETAMINE; NUCLEAR PROTEIN; PARVALBUMIN; PHOSPHOPROTEIN; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL DEATH; CELL LOSS; CELL SUBPOPULATION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL; NICK END LABELING; NISSL STAINING; NONHUMAN; PRIORITY JOURNAL;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERNEURONS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED ICR; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEURONS; NEUROTOXINS; NEUROTRANSMITTER AGENTS; NUCLEAR PROTEINS;

EID: 33646529834     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.02.055     Document Type: Article

References (85)

1. Albin R.L., Reiner A., Anderson K.D., Penney J.B., and Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease. implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 27 (1990) 357-365
2. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., Whetsell Jr. W.O., Penney J.B., and Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 31 (1992) 425-430
3. Alexander G.E., DeLong M.R., and Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9 (1986) 357-381
4. Arundine M., and Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 61 (2004) 657-668
5. Beal M.F. Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6 (1992) 3338-3344
6. Beal M.F., Ferrante R.J., Swartz K.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11 (1991) 1649-1659
7. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
8. Bolam J.P., Clarke D.J., Smith A.D., and Somogyi P. A type of aspiny neuron in the rat neostriatum accumulates [3H]gamma-aminobutyric acid. combination of Golgi-staining, autoradiography, and electron microscopy. J Comp Neurol 213 (1983) 121-134
9. Buening M.K., and Gibb J.W. Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity. Eur J Pharmacol 26 (1974) 30-34
10. Cadet J.L., and Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32 (1998) 117-131
11. Cadet J.L., Jayanthi S., and Deng X. Speed kills. cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17 (2003) 1775-1788
12. Calabresi P., De Murtas M., and Bernardi G. The neostriatum beyond the motor function. experimental and clinical evidence. Neuroscience 78 (1997) 39-60
13. Calabresi P., Centonze D., Gubellini P., Pisani A., and Bernardi G. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur J Neurosci 10 (1998) 2887-2895
14. Chen Q., and Reiner A. Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res 743 (1996) 346-352
15. Chen Q., Veenman C.L., and Reiner A. Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience 73 (1996) 715-731
16. Chen Q., Veenman L., Knopp K., Yan Z., Medina L., Song W.J., Surmeier D.J., and Reiner A. Evidence for the preferential localization of glutamate receptor-1 subunits of AMPA receptors to the dendritic spines of medium spiny neurons in rat striatum. Neuroscience 83 (1998) 749-761
17. Cicchetti F., Gould P.V., and Parent A. Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease. Brain Res 730 (1996) 232-237
18. Davidson C., Gow A.J., Lee T.H., and Ellinwood E.H. Methamphetamine neurotoxicity. necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36 (2001) 1-22
19. Dawson T.M., and Snyder S.H. Gases as biological messengers. nitric oxide and carbon monoxide in the brain. J Neurosci 14 (1994) 5147-5159
20. Dawson V.L., Dawson T.M., London E.D., Bredt D.S., and Snyder S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A 88 (1991) 6368-6371
21. Deng X., and Cadet J.L. Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice. Brain Res Mol Brain Res 83 (2000) 121-124
22. Deng X., Wang Y., Chou J., and Cadet J.L. Methamphetamine causes widespread apoptosis in the mouse brain. evidence from using an improved TUNEL histochemical method. Brain Res Mol Brain Res 93 (2001) 64-69
23. Deng Y.P., Albin R.L., Penney J.B., Young A.B., Anderson K.D., and Reiner A. Differential loss of striatal projection systems in Huntington's disease. a quantitative immunohistochemical study. J Chem Neuroanat 27 (2004) 143-164
24. Eisch A.J., and Marshall J.F. Methamphetamine neurotoxicity. dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 30 (1998) 433-445
25. Ferrante R.J., Kowall N.W., Beal M.F., Richardson Jr. E.P., Bird E.D., and Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 230 (1985) 561-563
26. Ferrer I., Friguls B., Dalfo E., Justicia C., and Planas A.M. Caspase-dependent and caspase-independent signalling of apoptosis in the penumbra following middle cerebral artery occlusion in the adult rat. Neuropathol Appl Neurobiol 29 (2003) 472-481
27. Forloni G., Lucca E., Angeretti N., Chiesa R., and Vezzani A. Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death. Role of cyclic GMP. J Neurochem 68 (1997) 319-327
28. Gerfen C.R. The neostriatal mosaic. multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15 (1992) 285-320
29. Gibb J.W., and Kogan F.J. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch Pharmacol 310 (1979) 185-187
30. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere M., and Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 79 (1997) 45-56
31. Hanson G.R., Rau K.S., and Fleckenstein A.E. The methamphetamine experience. a NIDA partnership. Neuropharmacology 47 Suppl 1 (2004) 92-100
32. Harvey D.C., Lacan G., and Melegan W.P. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp Brain Res 133 (2000) 349-358
33. Hickey M.A., and Chesselet M.F. Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 255-265
34. Hof P., Young W., Bloom F., Belichenko P., and Celio M.R. Comparative cytoarchitectonic atlas of the C57BL/6 and 129/Sv mouse brains (2000), Elsevier, New York
35. Hotchkiss A.J., and Gibb J.W. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214 (1980) 257-262
36. Hu H.J., Chen L.W., Yung K.K., and Chan Y.S. Differential expression of AMPA receptor subunits in substance P receptor-containing neurons of the caudate-putamen of rats. Neurosci Res 49 (2004) 281-288
37. Hynd M.R., Scott H.L., and Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45 (2004) 583-595
38. Imam S.Z., Crow J.P., Newport G.D., Islam F., Slikker Jr. W., and Ali S.F. Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice. protective effects of peroxynitrite decomposition catalyst. Brain Res 837 (1999) 15-21
39. Kawaguchi Y., Wilson C.J., Augood S.J., and Emson P.C. Striatal interneurones. chemical, physiological and morphological characterization. Trends Neurosci 18 (1995) 527-535
40. Kelley A.E., Delfs J.M., and Chu B. Neurotoxicity induced by the D-1 agonist SKF 38393 following microinjection into rat brain. Brain Res 532 (1990) 342-346
41. Koos T., and Tepper J.M. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2 (1999) 467-472
42. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penney Jr. J.B., and Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15 (1995) 5297-5307
43. Liang N.Y., and Rutledge C.O. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol 31 (1982) 983-992
44. Liang N.Y., and Rutledge C.O. Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem Pharmacol 31 (1982) 2479-2484
45. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330 (1994) 613-622
46. Loonam T.M., Noailles P.A., Yu J., Zhu J.P., and Angulo J.A. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum. Life Sci 73 (2003) 727-739
47. Marino M.J., Valenti O., and Conn P.J. Glutamate receptors and Parkinson's disease. opportunities for intervention. Drugs Aging 20 (2003) 377-397
48. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., and Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users. evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18 (1998) 8417-8422
49. McCann U.D., and Ricaurte G.A. Amphetamine neurotoxicity. accomplishments and remaining challenges. Neurosci Biobehav Rev 27 (2004) 821-826
50. Mitchell I.J., Cooper A.J., and Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 59 (1999) 691-719
51. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 258 (1992) 597-603
52. Nash J.F., and Yamamoto B.K. Methamphetamine neurotoxicity and striatal glutamate release. comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581 (1992) 237-243
53. O'Dell S.J., Weihmuller F.B., and Marshall J.F. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals. attenuation by dopamine D1 or D2 antagonists. J Neurochem 60 (1993) 1792-1799
54. Precht W., and Yoshida M. Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin. Brain Res 32 (1971) 229-233
55. Qin Z.H., Wang Y., and Chase T.N. Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain. Brain Res 725 (1996) 166-176
56. Raiteri M., Cerrito F., Cervoni A.M., and Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 208 (1979) 195-202
57. Rauca C., Schafer K., and Hollt V. Effects of somatostatin, octreotide and cortistatin on ischaemic neuronal damage following permanent middle cerebral artery occlusion in the rat. Naunyn Schmiedebergs Arch Pharmacol 360 (1999) 633-638
58. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85 (1988) 5733-5737
59. Richfield E.K., Maguire-Zeiss K.A., Vonkeman H.E., and Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol 38 (1995) 852-861
60. Richfield E.K., Vonsattel J.P., MacDonald M.E., Sun Z., Deng Y.P., and Reiner A. Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. Mov Disord 17 (2002) 327-332
61. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., and Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233 (1985) 539-544
62. Seiden L.S., Fischman M.W., and Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1 (1976) 215-219
63. Singer H.S., and Minzer K. Neurobiology of Tourette's syndrome. concepts of neuroanatomic localization and neurochemical abnormalities. Brain Dev 25 Suppl 1 (2003) S70-S84
64. Sonsalla P.K., Gibb J.W., and Hanson G.R. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 238 (1986) 932-937
65. Spalding K.L., Dharmarajan A.M., and Harvey A.R. Caspase-independent retinal ganglion cell death after target ablation in the neonatal rat. Eur J Neurosci 21 (2005) 33-45
66. Stephans S.E., and Yamamoto B.K. Methamphetamine-induced neurotoxicity. roles for glutamate and dopamine efflux. Synapse 17 (1994) 203-209
67. Stumm G., Schlegel J., Schafer T., Wurz C., Mennel H.D., Krieg J.C., and Vedder H. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J 13 (1999) 1065-1072
68. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15 (1995) 4102-4108
69. Szabo C. Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res Bull 41 (1996) 131-141
70. Thiriet N., Deng X., Solinas M., Ladenheim B., Curtis W., Goldberg S.R., Palmiter R.D., and Cadet J.L. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci 25 (2005) 5273-5279
71. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee J.Y., Toga A.W., Ling W., and London E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24 (2004) 6028-6036
72. Uemura Y., Kowall N.W., and Beal M.F. Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. Ann Neurol 27 (1990) 620-625
73. Villemagne V., Yuan J., Wong D.F., Dannals R.F., Hatzidimitriou G., Mathews W.B., Ravert H.T., Musachio J., McCann U.D., and Ricaurte G.A. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans. evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18 (1998) 419-427
74. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., and Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181 (1980) 151-160
75. Wang W.W., Cao R., Rao Z.R., and Chen L.W. Differential expression of NMDA and AMPA receptor subunits in DARPP-32-containing neurons of the cerebral cortex, hippocampus and neostriatum of rats. Brain Res 998 (2004) 174-183
76. Wilson C.J., and Groves P.M. Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum. a study employing intracellular inject of horseradish peroxidase. J Comp Neurol 194 (1980) 599-615
77. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., and Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2 (1996) 699-703
78. Xu W., Zhu J.P.Q., and Angulo J.A. Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse 58 (2005) 110-121
79. Yu J., Cadet J.L., and Angulo J.A. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 83 (2002) 613-622
80. Yu J., Wang J., Cadet J.L., and Angulo J.A. Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine-induced neurotoxicity in the mouse brain. Brain Res 1007 (2004) 124-131
81. Yung K.K., Smith A.D., Levey A.I., and Bolam J.P. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat. evidence from dopamine receptor and neuropeptide immunostaining. Eur J Neurosci 8 (1996) 861-869
82. Zhou F.M., Liang Y., and Dani J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4 (2001) 1224-1229
83. Zhu J.P.Q., Cadet J.L., and Angulo J.A. Blockade of neurokinin-1 receptors attenuates methamphetamine-induced TUNEL staining. Soc Neurosci Abstr 28 (2002) 701-709
84. Zhu J.P.Q., Xu W., and Angulo J.A. Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res 1049 (2005) 171-181
85. Zhu J.P.Q., Xu W., Angulo N., and Angulo J.A. Methamphetamine-induced striatal apoptosis in the mouse brain. Comparison of a binge to an acute bolus drug administration. Neurotoxicology 27 (2006) 131-136